New drug combo could replace chemo for lymphoma patients
NCT ID NCT03474744
First seen May 13, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This study tests a chemotherapy-free combination of two drugs, Copanlisib and Rituximab, in 36 people with marginal zone lymphoma (MZL) who need treatment but cannot have or have failed local therapy. The goal is to see if this combo works as well as standard chemo but with fewer side effects, especially for older patients. The main measure is complete response rate 12 months after starting treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Elblandkliniken Stiftung & Co. KG, Innere Medizin II
Riesa, 01589, Germany
-
Gemeinschaftspraxis, Fachärzte für Innere Medizin
Mannheim, 68161, Germany
-
Johanniter GmbH, Johanniter-Krankenhaus
Bonn, 53113, Germany
-
Kath. Karl-Leisner-Klinikum gGmbH, Betriebsstätte Wilhelm-Anton-Hospital
Goch, 47574, Germany
-
Kliniken Ostalb Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin
Mutlangen, 73557, Germany
-
Klinikum der Universität München, Medizinische Klinik und Poliklinik III
München, 83177, Germany
-
MVZ Goslar, MVZ Onkologische Kooperation Harz
Goslar, 38642, Germany
-
Med. Uni Wien AKH, Klinische Abteilung für Onkologie, Innere Medizin I
Vienna, 1190, Austria
-
Rotes Kreuz Krankenhaus, Klinik für Interdisziplinäre Onkologie
Kassel, 34121, Germany
-
Sana Klinikum Offenbach GmbH
Offenbach, 63069, Germany
-
St. Josef-Hospital, Medizinische Klinik I
Bochum, 44791, Germany
-
University Hospital Ulm
Ulm, 89081, Germany
-
Universitätsklinik PIUS Hospital, Innere Medizin
Oldenburg, 26121, Germany
-
Universitätsklinikum Halle, Klinik und Poliklinik für Innere Medizin
Halle, 06120, Germany
-
Universitätsmedizin Mannheim, III. Medizinische Klinik
Mannheim, 68167, Germany
-
Universitätsmedizin Rostock
Rostock, 18051, Germany
-
ÜBAG MVZ Dr. Vehling-Kaiser GmbH
Landshut, 84036, Germany
-
ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing
Dingolfing, 84113, Germany
Conditions
Explore the condition pages connected to this study.